We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $288M
1-Year Est. Return 313.93%
This Fund
S&P 500
This Quarter Est. Return
+22.99%
1 Year Est. Return
+313.93%
3 Year Est. Return
+546.33%
5 Year Est. Return
+596.42%
10 Year Est. Return
–
AUM
$288M
AUM Growth
-$72.3M
Cap. Flow
-$93.3M
Cap. Flow %
-32.42%
Top 10 Hldgs %
85.57%
Holding
20
New
–
Increased
–
Reduced
1
Closed
4

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$56.4M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$23.1M
3
GHRS icon
GH Research
GHRS
+$8.05M
4
SRZN icon
Surrozen
SRZN
+$3.19M
5
RLYB icon
Rallybio
RLYB
+$2.62M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MPLT
1
MapLight Therapeutics
MPLT
$584M
$34M 11.83%
950,011
– –
TYRA icon
2
Tyra Biosciences
TYRA
$1.49B
$32.9M 11.42%
1,029,298
– –
TRDA icon
3
Entrada Therapeutics
TRDA
$273M
$29.9M 10.37%
4,056,379
– –
PHVS icon
4
Pharvaris
PHVS
$2.48B
$27.6M 9.58%
797,600
– –
CAMP icon
5
CAMP4 Therapeutics
CAMP
$260M
$25.6M 8.91%
5,869,091
– –
ARTV
6
Artiva Biotherapeutics
ARTV
$542M
$22.8M 7.93%
2,353,304
– –
TECX
7
Tectonic Therapeutic
TECX
$696M
$20.9M 7.24%
606,660
– –
ZNTL icon
8
Zentalis Pharmaceuticals
ZNTL
$360M
$19.1M 6.65%
3,947,913
– –
CLDX icon
9
Celldex Therapeutics
CLDX
$3.07B
$18.5M 6.43%
497,270
– –
EYPT icon
10
EyePoint Inc
EYPT
$386M
$15M 5.22%
1,050,000
– –
BHVN icon
11
Biohaven
BHVN
$2.33B
$11M 3.82%
738,972
– –
SRZN icon
12
Surrozen
SRZN
$264M
$7.04M 2.45%
271,250
-116,250
-30% -$3.19M
SKYE icon
13
Skye Bioscience
SKYE
$7.86M
$6.71M 2.33%
1,210,220
– –
ALXO icon
14
ALX Oncology
ALXO
$277M
$6.33M 2.2%
3,057,325
– –
TARA icon
15
Protara Therapeutics
TARA
$226M
$5.23M 1.82%
1,369,782
– –
SLN
16
Silence Therapeutics
SLN
$834M
$5.23M 1.82%
476,200
– –
CNTA
17
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-580,945
Closed -$23.1M
ERAS icon
18
Erasca
ERAS
$6.31B
– –
-3,485,971
Closed -$56.4M
GHRS icon
19
GH Research
GHRS
$1.92B
– –
-572,665
Closed -$8.05M
RLYB icon
20
Rallybio
RLYB
$89.3M
– –
-291,788
Closed -$2.62M

Similar funds

TA
TKG Advisors Valparaiso, Indiana $288M AUM 43.58% 1-Year Est. Return
APW
Alliance Private Wealth North Reading, Massachusetts $288M AUM
RCS
Retirement Capital Strategies San Jose, California $288M AUM 17.43% 1-Year Est. Return
FH
FWG Holdings Winter Park, Florida $288M AUM 33.26% 1-Year Est. Return
IAMOG
Investors Asset Management of Georgia Atlanta, Georgia $288M AUM 47.58% 1-Year Est. Return
MP
Maestria Partners Atlanta, Georgia $288M AUM 13.77% 1-Year Est. Return
OL
Owen LaRue Elizabethtown, Kentucky $288M AUM 29.4% 1-Year Est. Return
CFG
Cambridge Financial Group Columbus, Ohio $287M AUM 33.96% 1-Year Est. Return

5AM Venture Management's Q2 2026 Portfolio in Review

As of Q2 2026, 5AM Venture Management held 20 positions worth $288M, down 20% from $360M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

5AM Venture Management withdrew a net $93.3M in Q2 2026, closing 4 positions and reducing 1 holding. Its most notable exit was Erasca, an estimated $56.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • 5AM Venture Management's biggest Q2 2026 reduction was Surrozen, cutting an estimated $3.19M.
  • 5AM Venture Management fully exited Erasca in Q2 2026, selling an estimated $56.4M.
  • 5AM Venture Management's ten largest holdings make up 86% of its $288M portfolio in Q2 2026.
  • 5AM Venture Management opened 0 new positions and closed 4 in Q2 2026.
  • 5AM Venture Management's portfolio value fell 20% quarter-over-quarter to $288M.

Based on 5AM Venture Management's 13F filing for Q2 2026, filed 14 Aug 2026.